Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Neoplasms | 19 | 2021 | 17251 | 1.21 | Why? |
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2020 | 13 | 0.85 | Why? |
| Venous Thromboembolism | 7 | 2021 | 4273 | 0.62 | Why? |
| Observational Studies as Topic | 2 | 2021 | 1887 | 0.62 | Why? |
| Comparative Effectiveness Research | 1 | 2012 | 178 | 0.46 | Why? |
| Breast Neoplasms | 4 | 2020 | 3633 | 0.38 | Why? |
| Medical Oncology | 3 | 2020 | 3826 | 0.35 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.33 | Why? |
| Immunotherapy | 1 | 2020 | 2421 | 0.33 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.33 | Why? |
| Precision Medicine | 2 | 2018 | 1477 | 0.32 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.28 | Why? |
| Research Design | 2 | 2020 | 5830 | 0.28 | Why? |
| Rivaroxaban | 2 | 2019 | 467 | 0.27 | Why? |
| Factor Xa Inhibitors | 2 | 2019 | 490 | 0.25 | Why? |
| Antineoplastic Agents | 2 | 2019 | 3550 | 0.25 | Why? |
| Filgrastim | 1 | 2020 | 25 | 0.21 | Why? |
| Genomics | 1 | 2012 | 3118 | 0.21 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.21 | Why? |
| Publication Bias | 1 | 2021 | 241 | 0.20 | Why? |
| Comprehensive Health Care | 1 | 2020 | 153 | 0.20 | Why? |
| Soft Tissue Neoplasms | 1 | 2021 | 131 | 0.20 | Why? |
| Biomarkers, Tumor | 2 | 2019 | 1314 | 0.19 | Why? |
| Chemotherapy, Adjuvant | 2 | 2019 | 606 | 0.19 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.18 | Why? |
| DNA Copy Number Variations | 1 | 2018 | 84 | 0.18 | Why? |
| Sarcoma | 1 | 2021 | 290 | 0.17 | Why? |
| Dalteparin | 1 | 2017 | 57 | 0.17 | Why? |
| Drug Utilization | 1 | 2020 | 619 | 0.14 | Why? |
| Pulmonary Embolism | 3 | 2018 | 4775 | 0.14 | Why? |
| Decision Support Systems, Clinical | 1 | 2019 | 551 | 0.13 | Why? |
| Decision Support Techniques | 2 | 2018 | 903 | 0.13 | Why? |
| Gene Regulatory Networks | 1 | 2018 | 820 | 0.12 | Why? |
| Humans | 28 | 2021 | 930598 | 0.12 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.11 | Why? |
| Genital Neoplasms, Female | 1 | 2018 | 718 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.10 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.10 | Why? |
| Ambulatory Care | 2 | 2018 | 4947 | 0.10 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.10 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.10 | Why? |
| Drug Approval | 1 | 2018 | 1325 | 0.09 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.09 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.08 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.08 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.08 | Why? |
| Social Support | 1 | 2020 | 3183 | 0.08 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.08 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.07 | Why? |
| Aged | 10 | 2021 | 215776 | 0.07 | Why? |
| Blood Coagulation | 1 | 2017 | 2768 | 0.07 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.07 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.06 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.06 | Why? |
| Registries | 2 | 2020 | 12327 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Female | 14 | 2021 | 380317 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2020 | 3893 | 0.06 | Why? |
| Decision Making | 2 | 2017 | 3132 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2017 | 2739 | 0.06 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.06 | Why? |
| Male | 12 | 2021 | 367725 | 0.06 | Why? |
| Hemorrhage | 3 | 2019 | 3013 | 0.05 | Why? |
| Practice Guidelines as Topic | 3 | 2021 | 15421 | 0.05 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.05 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.05 | Why? |
| United States | 4 | 2020 | 46150 | 0.05 | Why? |
| Chemoradiotherapy | 1 | 2021 | 362 | 0.05 | Why? |
| Triple Negative Breast Neoplasms | 1 | 2019 | 92 | 0.05 | Why? |
| Receptor, ErbB-2 | 1 | 2019 | 267 | 0.04 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2021 | 10697 | 0.04 | Why? |
| Receptors, Estrogen | 1 | 2018 | 171 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2019 | 673 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2019 | 582 | 0.04 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Clinical Decision-Making | 2 | 2020 | 3755 | 0.04 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2019 | 1654 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.03 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.03 | Why? |
| Aged, 80 and over | 3 | 2019 | 88759 | 0.03 | Why? |
| Organ Specificity | 1 | 2018 | 1070 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| RNA, Long Noncoding | 1 | 2018 | 408 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Databases, Genetic | 1 | 2018 | 1127 | 0.03 | Why? |
| Neoplasm Recurrence, Local | 1 | 2019 | 1063 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1014 | 0.03 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Adult | 4 | 2021 | 244371 | 0.02 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.02 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
Kuderer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(120)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(236)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_